Suche
Ihre Suche nach "%2A" ergab 110 Treffer
- Beyer, Sarah Rosa
- Identifikation kritischer Cysteinreste im humanen kationischen Aminosäuretransporter 2A (hCAT-2A)
- Mainz: Univ. 2013 126 S.
- Pharmakogenetische Diagnostik zur Genotypisierung von UGT1A1*28 und DPYD*2A
- Rossmann, Heidi; (2007)
- Makhoul, Stephanie; Kumm, Elena; Zhang, Pengyu et al.
- The Serine/Threonine Protein Phosphatase 2A (PP2A) Regulates Syk Activity in Human Platelets
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Bd. 21. H. 23. 2020
- Loquai, C; Nashan, D; Hensen, P et al.
- Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
- Eur J Dermatol. Bd. 18. H. 1. 2008 S. 29-35
- zur Zurwiesch, JS; Pudelski, N; Hoepner, L et al.
- "Real-Life" Comparison of Pegylated-Interferon 2a Versus 2b Combination Therapy of Chronic Hepatitis C Virus
- HEPATOLOGY. Bd. 53. H. 4. 2011 S. 1405-1406
- Göder, Anja; Emmerich, Claudia; Nikolova, Teodora et al.
- HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130
- Nature communications. Bd. 9. London: Nature Publishing Group UK 2018 Art. 764
- Freitag, Christine M.; Agelopoulos, Konstantin; Huy, Ellen et al.
- Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder
- EUROPEAN CHILD & ADOLESCENT PSYCHIATRY. Bd. 19. H. 1. 2010 S. 67 - 74
- Goeder, Anja; Emmerich, Claudia; Nikolova, Teodora et al.
- HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130
- NATURE COMMUNICATIONS. Bd. 9. 2018
- Moreno, Estefania; Chiarlone, Anna; Medrano, Mireia et al.
- Singular Location and Signaling Profile of Adenosine A(2A)-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum
- NEUROPSYCHOPHARMACOLOGY. Bd. 43. H. 5. 2018 S. 964-977
- Zehnter, E; Mauss, S; Boeker, K et al.
- EFFICACY AND TOLERABILITY OF PEGINTERFERON ALPHA-2A (40KD) AND RIBAVIRIN IN RELAPSE-PATIENTS UNDER REAL-LIFE CONDITIONS
- HEPATOLOGY. Bd. 52. H. 4. 2010 S. 799A-800A
- Mauss, S; Schober, A; Lutz, T et al.
- Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin
- GASTROENTEROLOGY. Bd. 140. H. 5. 2011 S. S948-S948
- Mauss, S; Schober, A; Lutz, T et al.
- PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN
- JOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S185-S185
- Beyer, Sarah R.; Mallmann, Robert T.; Jaenecke, Isabel et al.
- Identification of cysteine residues in human cationic amino acid transporter hCAT-2A that are targets for inhibition by N-ethylmaleimide
- The journal of biological chemistry. Bd. 288. H. 42. Bethesda, Md.: Soc. 2013 S. 30411 - 30419
- Frank-Raue, K; Rybicki, LA; Erlic, Z et al.
- Risk Profiles and Penetrance Estimations in Multiple Endocrine Neoplasia Type 2A Caused by Germline RET Mutations Located in Exon 10
- HUMAN MUTATION. Bd. 32. H. 1. 2011 S. 51-58
- Frank-Raue, K; Rybicki, LA; Erlic, Z et al.
- Risk profiles and penetrance estimations in mutliple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10
- Hum Mutat. 2010 S. 1
- Siebels, M; Rohrmann, K; Oberneder, R et al.
- A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(A (R))) and interferon-alpha-2a in metastatic renal cell carcinoma patients
- WORLD JOURNAL OF UROLOGY. Bd. 29. H. 1. 2011 S. 121-126
- Sulkowski, Mark S.; Bourliere, Marc; Bronowicki, Jean-Pierre et al.
- Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
- HEPATOLOGY. Bd. 57. H. 6. 2013 S. 2155-2163
- Sulkowski, Mark S.; Asselah, Tarik; Lalezari, Jacob et al.
- Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype1 HCV: SILEN-C1 trial
- HEPATOLOGY. Bd. 57. H. 6. 2013 S. 2143-2154
- Rossol, S; Schuchmann, M; Mauss, S et al.
- PHARMAECONOMIC EVALUATION OF CHRONIC HCV TREATMENT WITH PEGINTERFERON ALFA-2A/RIBAVIRN - REAL LIFE SETTING IN A LARGE GERMAN COHORT OF 1147 PATIENTS
- HEPATOLOGY. Bd. 54. 2011 S. 858A-859A
- Schaefer, M; Sarkar, R; Knop, V et al.
- Escitalopram for the Prevention of Peginterferon-alpha 2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease A Randomized Trial
- ANNALS OF INTERNAL MEDICINE. Bd. 157. H. 2. 2012 S. 94-+
- Niederau, Claus; Mauss, Stefan; Schober, Andreas et al.
- Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon alpha-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3
- PLOS ONE. Bd. 9. H. 9. 2014
- Dieterich, Douglas; Asselah, Tarik; Guyader, Dominique et al.
- SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon alpha-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
- ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. Bd. 58. H. 6. 2014 S. 3429-3436
- Boeker, K; Mauss, S; Zehnter, E et al.
- SVR AND ANEMIA IN HCV-GENOTYPE 1 PATIENTS TREATED WITH PEG-INTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV): LITTLE EFFECT OF RIBAVIRIN DOSAGE
- HEPATOLOGY. Bd. 52. H. 4. 2010 S. 768A-769A
- Larrey, D; Lohse, AW; de Ledinghen, V et al.
- Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin
- JOURNAL OF HEPATOLOGY. Bd. 57. H. 1. 2012 S. 39-46
- Huesken, A. C.; Tsianakas, A.; Hensen, P. et al.
- Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma
- JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. Bd. 26. H. 1. 2012 S. 71-78
- Stenger, Thorsten Max
- Einfluss der kleinen G-Proteine RhoA, Rac1 und Cdc42 auf das Transportverhalten und die Proteinkinase C-vermittelte Regulation des humanen kationischen Aminosäuretransporter hCAT-2A
- Mainz: Univ. 2012 142 S.
- Christensen, Stefan; Boeker, Klaus H.; Eisenbach, Christoph et al.
- Efficacy and safety of eRVR patients treated with telaprevir, peginterferon alfa-2A and ribavirin: SVR Data from the German non-interventional PAN Study
- HEPATOLOGY. Bd. 58. 2013 S. 1127A-1127A
- Lohse, AW; Böcher, WO; Biesterfeld, S et al.
- Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation
- Transpl Int. Bd. 20. 2007 S. 583-590
- Hueppe, D; Zehnter, E; Mauss, S et al.
- Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) (PEG) and Ribavirin (RBV) in Genotype 5 and 6 Patients with Chronic Hepatitis C Under Real Life Conditions
- GASTROENTEROLOGY. Bd. 136. H. 5. 2009 S. A839-A840
- Mauss, S.; Boeker, K. H. W.; Eisenbach, C. et al.
- REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
- JOURNAL OF HEPATOLOGY. Bd. 58. 2013 S. S357-S358
- Zimmermann, Tim; Hueppe, Dietrich; Mauss, Stefan et al.
- Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naive Patients Infected with Hepatitis C Virus Genotype 1
- JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES. Bd. 25. H. 1. 2016 S. 15-24
- Christensen, S.; Mauss, S.; Eisenbach, C. et al.
- WEEK 4 AND 12 EFFICACY OF TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON alfa 2a/RIBAVIRIN (P/R) IN TREATMENT EXPERIENCED PATIENTS WITH GT-1 UNDER REAL LIFE CONDITIONS
- JOURNAL OF HEPATOLOGY. Bd. 58. 2013 S. S329-S329
- Boeker, K; Mauss, S; Hueppe, D et al.
- Dose Reduction of Peginterferon Alfa-2a (PEG) in Combination With Ribavirin (RBV) in Chronic Hepatitis C (CHC) Patients: Impact on Virological Response Under Real Life Conditions
- GASTROENTEROLOGY. Bd. 140. H. 5. 2011 S. S948-S948
- Boeker, K; Mauss, S; Hueppe, D et al.
- DOSE REDUCTION OF PEGINTERFERON ALFA-2A (PEG) IN COMBINATION WITH RIBAVIRIN (RBV) IN CHRONIC HEPATITIS C (CHC) PATIENTS: IMPACT ON VIROLOGICAL RESPONSE UNDER REAL LIFE CONDITIONS
- JOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S162-S162
- Zehnter, E; Hueppe, D; Kaiser, S et al.
- ROLE OF RVR AND VIRAL LOAD ON SVR IN TREATMENT OF GT3 HEPATITIS C PATIENTS WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE
- JOURNAL OF HEPATOLOGY. Bd. 50. 2009 S. S239-S240
- Zeuzem, S; Arora, S; Bacon, B et al.
- PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
- JOURNAL OF HEPATOLOGY. Bd. 56. 2012 S. S5-S6
- Moreno, Christophe; Ferenci, Peter; Asselah, Tarik et al.
- Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naive Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
- AMERICAN JOURNAL OF GASTROENTEROLOGY. Bd. 108. 2013 S. S145-S145
- Sprinzl, Martin; Grambihler, Annette; Teuber, Gerlinde et al.
- Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial
- JOURNAL OF HEPATOLOGY. Bd. 70. 2019 S. E485-E485
- Dieterich, D; Asselah, T; Guyader, D et al.
- SILEN-C3: TREATMENT FOR 12 OR 24 WEEKS WITH BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAiVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION
- HEPATOLOGY. Bd. 54. 2011 S. 378A-378A
- Moog, Gero; Mauss, Stefan; Hueppe, Dietrich et al.
- Triple Therapy Under Real Life Conditions: Telaprevir (TVR) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in NaiVE Patients Infected With Chronic Hepatitis C, Genotype 1. The PAN Study
- GASTROENTEROLOGY. Bd. 144. H. 5. 2013 S. S983-S983
- Ferenci, P.; Asselah, T.; Foster, G. R. et al.
- Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial
- JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. Bd. 28. 2013 S. 157-158
- Ferenci, P.; Asselah, T.; Foster, G. R. et al.
- FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL
- JOURNAL OF HEPATOLOGY. Bd. 58. 2013 S. S569-S570
- Zeuzem, S; Arora, S; Bacon, B et al.
- PEGYLATED INTERFERON-LAMBDA (PEGIFN-lambda) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFN alpha-2A IN HCV PATIENTS (G1/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
- JOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S538-S539
- Jacobson, Ira M.; Asselah, Tarik; Ferenci, Peter et al.
- STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection
- HEPATOLOGY. Bd. 58. 2013 S. 742A-743A
- Altrichter, S.; Staubach, P.; Pasha, M. et al.
- Efficacy and safety data of AK002, an anti-siglec-8 monoclonal antibody, in patients with multiple forms of uncontrolled chronic urticaria (CU): Results from an open-label phase 2a study
- ALLERGY. Bd. 74. 2019 S. 120-120
- Sprinzl, M.; Grambihler, A.; Teuber, G. et al.
- Addition of pegylated interferon alfa-2a to an ongoing nucleos(t) ide treatment accelerates decrease of HBs-antigen levels in patients with chronic hepatitis B: Results from the PADD-ON study
- JOURNAL OF HEPATOLOGY. Bd. 68. 2018 S. S108-S109
- Yoshida, Eric M.; Asselah, Tarik; Moreno, Christophe et al.
- Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: A pooled analysis of STARTVerso1 and 2
- HEPATOLOGY. Bd. 58. 2013 S. 751A-752A